{
    "root": "42b22ad0-4838-43fd-9bf7-f22dafc7c352",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "Human Prescription Drug Label",
    "name": {
        "text": "Abacavir and Lamivudine"
    },
    "value": "20250303",
    "ingredients": [
        {
            "name": "ABACAVIR SULFATE",
            "code": "J220T4J9Q2"
        },
        {
            "name": "LAMIVUDINE",
            "code": "2T8Q726O95"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED",
            "code": "2165RE0K14"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        }
    ],
    "indications": "Abacavir and lamivudine tablets, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.",
    "contraindications": "• Before initiating abacavir and lamivudine tablets, screen for the HLA-B*5701 allele because abacavir and lamivudine tablets contains abacavir. ( 2.1 ) • Adults: One tablet orally once daily. ( 2.2 ) • Pediatric patients weighing at least 25 kg: One tablet daily. ( 2.3 ) • Because abacavir and lamivudine tablets is a fixed-dose tablet and cannot be dose adjusted, abacavir and lamivudine tablets is not recommended in    patients with creatinine clearance less than 30 mL per minute or patients with hepatic impairment. ( 2.4 , 4 )",
    "warningsAndPrecautions": "Abacavir and lamivudine tablets, USP is available as tablets. Each tablet contains 600 mg of abacavir as abacavir sulfate and 300 mg of lamivudine. The tablets are orange, biconvex film-coated, modified capsule-shaped, and debossed with I 60 on one side with no markings on the reverse side. They are packaged as follows:\n                  Bottles of 30 tablets (NDC 33342-440-07). Carton of 30 tablets (5x6 unit dose) (NDC 33342-440-14). Carton of 60 tablets (10x6 unit dose) (NDC 33342-440-98).\n                  Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F) \n                     [see USP Controlled Room Temperature].",
    "adverseReactions": "Abacavir and lamivudine tablets is contraindicated in patients: • who have the HLA-B*5701 allele [see Warnings and Precautions (\n                     \n                        5.1\n                     \n                     )].\n                      • with prior hypersensitivity reaction to abacavir [see Warnings and Precautions (\n                     \n                        5.1\n                     \n                     )] or lamivudine. • with moderate or severe hepatic impairment [see Use in Specific Populations (\n                     \n                        8.7\n                     \n                     )]."
}